Results 61 to 70 of about 10,001 (127)
ACR Open Rheumatology, Volume 7, Issue 12, December 2025.Objective A cardiovascular safety issue has been associated with JAK inhibitors (JAKi). This study compares the effects of distinct approved JAKi on endothelial cell (EC) dysfunction and apoptosis during inflammation. Methods Massive inflammation was induced in human vascular ECs by tumor necrosis factor (TNF) with interleukin‐17A (IL‐17A) treated or ...
Aliki Zavoriti, Pierre Miossec
wiley +1 more source
Cancer Medicine, Volume 14, Issue 23, December 2025.ABSTRACT Background Symptom management in myeloproliferative neoplasms (MPN) remains challenging despite advancements in disease‐directed therapies. This study assessed the impact of demographic, clinical, laboratory and treatment‐related variables on total symptom scores (TSS) and individual symptom scores in patients with polycythemia vera (PV ...
Muhammad Ali Khan +8 more
wiley +1 more source
Journal of Clinical Apheresis, Volume 40, Issue 6, December 2025.ABSTRACT Chronic graft‐versus‐host disease (cGVHD) remains a major cause of morbidity and mortality following allogeneic hematopoietic stem cell transplantation. Many cGVHD patients require prolonged systemic immunosuppression with corticosteroids, which carry significant adverse effects, and alternative therapies are often required.
Yitzhar Goretsky +18 more
wiley +1 more source
eJHaem, Volume 6, Issue 6, December 2025.ABSTRACT Introduction Ruxolitinib is a key therapeutic option for patients with myeloproliferative neoplasms. Its short‐term toxicity profile is well‐established, but long‐term safety data remains scarce. Methods We aimed to evaluate toxicity associated with long‐term exposure to ruxolitinib (defined as 3 years or longer) through a dual‐cohort ...
Alberto Blanco‐Sánchez +8 more
wiley +1 more source
Revista Brasileira de Hematologia e Hemoterapia, 2014 Objective: The aim of this work was to demonstrate a possible relationship between anti-latency-associated peptide human latent transforming growth factor beta 1 (latent TGF-β1) expression in megakaryocytes and microvascular density in bone marrow ...
Cesar Cilento Ponce +3 more
doaj +1 more source
What's Your Diagnosis? A Case of Extreme Thrombocytosis in a Dog
Veterinary Clinical Pathology, EarlyView.
Stephanie F. Anderson +5 more
wiley +1 more source
Novel Nonsense Mutation in SMARCD2 Gene Results in Dysplasia of All Myeloid Cell Lines
eJHaem, Volume 6, Issue 6, December 2025.ABSTRACT Introduction Specific granule deficiency type II (SGD2) is a rare heterogeneous congenital disease characterized by early‐onset life‐threatening infections. SGD2 is caused by autosomal recessive mutations in the SMARCD2 gene. Methods Prenatal screening in our patient revealed a novel homozygous nonsense mutation in SMARCD2 (c.208C>T, p.Gln70*).
Michelle A. E. Brouwer +6 more
wiley +1 more source
Gray platelet syndrome: proinflammatory megakaryocytes and α-granule loss cause myelofibrosis and confer metastasis resistance in mice [PDF]
, 2014 José A. Guerrero +14 more
openalex +1 more source